The clinical impact of epilepsy genetics

Abstract
An overemphasis on molecular genetic advances in epilepsy is in danger of missing the major contribution that clinical genetic studies make in predicting the likely benefit of molecular research efforts. Genetic epidemiology, twin, and family studies suggest that some individual epilepsy genes raise the risk for developing many different types of epilepsy but that specific combinations of these genes determine specific epilepsy phenotypes. Experimental data show how differences in drug response can result from inherited differences in drug sensitivity and there is emerging data on the genetic basis of harmful adverse drug reactions and teratogenesis. These developments predict a future in which epilepsy is ultimately classified on the basis of its oligogenic architecture, effective treatments are tailored to the appropriate patient and harmful adverse drug reactions avoided in those who are sensitive.

Epilepsy can be classified as idiopathic (where no aetiology other than a genetic predisposition is identified), symptomatic (epilepsy occurring as a result of identified brain lesion), and cryptogenic (where symptomatic epilepsy is suspected but an underlying brain lesion is not identified). With advances in genetics and neuroimaging the prevalence of cryptogenic epilepsy is falling.

The role of inheritance in epilepsy is traditionally categorised according to the mechanism of inheritance: (1) mendelian disorders in which epilepsy forms part of the phenotype; (2) idiopathic epilepsies with mendelian inheritance; (3) epilepsies with complex inheritance; (4) idiopathic epilepsies associated with cytogenetic abnormality.

There are over 200, individually rare, mendelian disorders in which epilepsy forms part of the phenotype. These include neurocutaneous disorders, neurodegenerative disorders, inherited malformations of cortical development, and an array of inherited metabolic disorders. Examples of recent interest are discussed elsewhere and although important, are not the focus of this editorial. Rare epilepsies with cytogenetic abnormality, as well as those demonstrating simple mendelian inheritance, are similarly rare and account for an estimated 1% of all epilepsy. Epilepsies in which the sole aetiology is a complex genetic predisposition are common and account for a minimum 50% of all epilepsy.

Defining the genetic component to epilepsy phenotypes
Two important studies have examined the genetic basis to epilepsy phenotype. Berkovic tested the hypothesis that major epilepsy syndromes are distinct genetic entities determined by syndrome specific genes or combinations of genes. In this key study, MZ and DZ twin pairs concordant for epilepsy were found to be equally highly concordant for major epilepsy syndrome. Although the high concordance for epilepsy phenotype amongst MZ and DZ twin pairs concordant for epilepsy could have resulted from shared environmental factors, the biological implausibility of this argument strongly suggests that specific epilepsy genes determine both the presence of epilepsy and its specific clinical characteristics. This has clear practical importance in terms of the potential to accurately predict a person’s epilepsy phenotype (and not just their risk of developing epilepsy) on the basis of their epilepsy genetic aetiology. Furthermore, twin studies suggest that the potential to predict epilepsy phenotype may extend to predicting epilepsy prognosis. Amongst twin pairs concordant for seizures and in whom one or other twin reported status
The clinical impact of epilepsy genetics

The genetic basis for epilepsy phenotypes has also been considered using genetic epidemiology. Rate ratios for generalised and partial epilepsy were calculated in first degree relatives of 1498 adult probands with either partial or generalised epilepsy. Here, the authors found that the increased risk of epilepsy in first degree relatives was not necessarily restricted to the same type of epilepsy as in the proband. This finding provides evidence that some epilepsy genes have the potential to contribute to multiple epilepsy phenotypes, both partial and generalised. The hypothesis that specific combinations of epilepsy genes determine specific epilepsy phenotypes but that individual epilepsy genes have the potential to contribute to different types of epilepsy.

Simple mendelian epilepsies are complex

Although individually rare, the genetic analysis of “simple” mendelian epilepsies has been a key strategy in advancing our understanding of epilepsy. Six genes which, when mutated, may result in idiopathic epilepsy have been identified (table 1). Each of these genes encodes a subunit for a neurotransmitter (nAChR, CHRNA4 or a neurotransmitter (CHRN2). It is not known whether mutations or polymorphisms in these genes confer increased risk for more common epilepsies. Despite disclosing idiopathic epilepsies as “ion channelopathies,” identification of these genes has done little to explain the complex relation between genotype and epilepsy phenotype. It is already clear that specific epilepsy phenotypes can have more than one genetic cause. For example, mutations in both the α-4 subunit gene (CHRNA4) and the β-2 subunit gene (CHRN2) of the neuronal nicotinic acetylcholine receptor (nAChR) are associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and neurofibromatosis type 1 (NF1). The explanation is concealed in a commonly held, but oversimplified view of “simple” Mendelian inheritance. Linkage analysis, which tracks a gene as it segregates through a pedigree, tracks only the “main effect” of a gene—that is, that which determines the average phenotypic effect taken above all other genes with which it may, or may not interact. Twenty years of linkage analysis in mendelian disorders has contributed to a widely held view that such disorders are caused by mutations in single genes. In reality, the situation is much more complex. For example, the main effect of the SCN1B mutation is to raise the risk for the multiple seizure types that constitute the family epilepsy syndrome of GEFS+. Whether a person with this mutation develops seizures and what seizure type they develop is, however, determined by the interaction of the SCN1B mutation with other genetic and/or environmental factors. For this and other “simple” mendelian epilepsies, the phenotypes of patients are, in fact, complex traits. It is clear that accurate genotype-phenotype correlations will only come about when the complete genetic architecture of a person’s epilepsy is revealed. This is the real challenge facing epilepsy genetics. An overemphasis on the causal relation of single genes to epilepsy is in danger of missing the major contribution other genetic factors make in determining a person’s epilepsy phenotype.

Epilepsy and pharmacogenetics

Pharmacogenetics aims to predict therapeutic drug response and adverse drug reactions on the basis of inherited differences to drug sensitivity.

Drug resistant epilepsy is a major problem and genetic mechanisms may contribute to refractoriness via pharmacodynamic or pharmacokinetic mechanisms. Alteration of the pharmacodynamic response to antiepileptic drugs (AEDs) might be influenced by genetic differences in receptor subunits and important evidence showing how the pharmacodynamic response to benzodiazepines can be genetically modified has been presented. Pharmacokinetic mechanisms might also act to influence drug resistance in epilepsy. Multidrug resistance (MDR) is a term used to describe the phenomenon some tumours exhibit of simultaneous resistance to some structurally and functionally unrelated chemotherapeutic agents. The human MDR-1 gene encodes an integral membrane protein, P-glycoprotein, the function of which is the energy dependent transport of molecules across membranes. Increased expression of P-glycoprotein in the brain of some patients with medically intractable epilepsy has been demonstrated suggesting that MDR proteins may play a part in determining the pharmacokinetic profile of AEDs within the blood-brain barrier. Functional polymorphisms in

---

### Table 1: Epilepsy genes

<table>
<thead>
<tr>
<th>Gene</th>
<th>Locus</th>
<th>Epilepsy</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHRNA4</td>
<td>20q</td>
<td>ADNFLE</td>
<td>11</td>
</tr>
<tr>
<td>CHRN2</td>
<td>1q</td>
<td>ADNFLE</td>
<td>12</td>
</tr>
<tr>
<td>KCNQ2</td>
<td>20q</td>
<td>BFNC</td>
<td>13, 14</td>
</tr>
<tr>
<td>KCNQ3</td>
<td>8q</td>
<td>BFNC</td>
<td>15</td>
</tr>
<tr>
<td>SCN1B</td>
<td>19q</td>
<td>GEFS+</td>
<td>16</td>
</tr>
<tr>
<td>SCN1A</td>
<td>2q</td>
<td>GEFS+</td>
<td>2, 17</td>
</tr>
</tbody>
</table>

ADNFLE=autosomal dominant nocturnal frontal lobe epilepsy; BFNC=benign familial neonatal convulsions; GEFS+=generalised epilepsy with febrile seizures plus.

The clinical impact of epilepsy genetics

The genetic basis for epilepsy phenotypes has also been considered using genetic epidemiology. Rate ratios for generalised and partial epilepsy were calculated in first degree relatives of 1498 adult probands with either partial or generalised epilepsy. Here, the authors found that the increased risk of epilepsy in first degree relatives was not necessarily restricted to the same type of epilepsy as in the proband. This finding provides evidence that some epilepsy genes have the potential to contribute to multiple epilepsy phenotypes, both partial and generalised. The hypothesis that specific combinations of epilepsy genes determine specific epilepsy phenotypes but that individual epilepsy genes have the potential to contribute to different types of epilepsy.

Simple mendelian epilepsies are complex

Although individually rare, the genetic analysis of “simple” mendelian epilepsies has been a key strategy in advancing our understanding of epilepsy. Six genes which, when mutated, may result in idiopathic epilepsy have been identified (table 1). Each of these genes encodes a subunit for a neurotransmitter (nAChR, CHRNA4 or a neurotransmitter (CHRN2). It is not known whether mutations or polymorphisms in these genes confer increased risk for more common epilepsies. Despite disclosing idiopathic epilepsies as “ion channelopathies,” identification of these genes has done little to explain the complex relation between genotype and epilepsy phenotype. It is already clear that specific epilepsy phenotypes can have more than one genetic cause. For example, mutations in both the α-4 subunit gene (CHRNA4) and the β-2 subunit gene (CHRN2) of the neuronal nicotinic acetylcholine receptor (nAChR) are associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and neurofibromatosis type 1 (NF1). The explanation is concealed in a commonly held, but oversimplified view of “simple” Mendelian inheritance. Linkage analysis, which tracks a gene as it segregates through a pedigree, tracks only the “main effect” of a gene—that is, that which determines the average phenotypic effect taken above all other genes with which it may, or may not interact. Twenty years of linkage analysis in mendelian disorders has contributed to a widely held view that such disorders are caused by mutations in single genes. In reality, the situation is much more complex. For example, the main effect of the SCN1B mutation is to raise the risk for the multiple seizure types that constitute the family epilepsy syndrome of GEFS+. Whether a person with this mutation develops seizures and what seizure type they develop is, however, determined by the interaction of the SCN1B mutation with other genetic and/or environmental factors. For this and other “simple” mendelian epilepsies, the phenotypes of patients are, in fact, complex traits. It is clear that accurate genotype-phenotype correlations will only come about when the complete genetic architecture of a person’s epilepsy is revealed. This is the real challenge facing epilepsy genetics. An overemphasis on the causal relation of single genes to epilepsy is in danger of missing the major contribution other genetic factors make in determining a person’s epilepsy phenotype.

Epilepsy and pharmacogenetics

Pharmacogenetics aims to predict therapeutic drug response and adverse drug reactions on the basis of inherited differences to drug sensitivity.

Drug resistant epilepsy is a major problem and genetic mechanisms may contribute to refractoriness via pharmacodynamic or pharmacokinetic mechanisms. Alteration of the pharmacodynamic response to antiepileptic drugs (AEDs) might be influenced by genetic differences in receptor subunits and important evidence showing how the pharmacodynamic response to benzodiazepines can be genetically modified has been presented. Pharmacokinetic mechanisms might also act to influence drug resistance in epilepsy. Multidrug resistance (MDR) is a term used to describe the phenomenon some tumours exhibit of simultaneous resistance to some structurally and functionally unrelated chemotherapeutic agents. The human MDR-1 gene encodes an integral membrane protein, P-glycoprotein, the function of which is the energy dependent transport of molecules across membranes. Increased expression of P-glycoprotein in the brain of some patients with medically intractable epilepsy has been demonstrated suggesting that MDR proteins may play a part in determining the pharmacokinetic profile of AEDs within the blood-brain barrier. Functional polymorphisms in
P-glycoprotein have been demonstrated and testing the hypothesis that such polymorphisms confer refractoriness to AEDs is an area of intense activity. In addition to therapeutic drug response, certain adverse drug reactions may also have a genetic basis. Anticonvulsant hypersensitivity syndrome is a potentially fatal drug reaction with an estimated incidence of 1 in 10 000 new drug exposures. Allergic sensitivity to toxic arene oxide intermediates is proposed as a possible mechanism and fatal anticonvulsant hypersensitivity syndrome occurring in a man with a functional epoxide hydrolase defect has been described. Whereas this defect may have resulted from the anticonvulsant drug itself, sepsis, or treatment with corticosteroids, the potential for it to be genetically based is increased by the finding of familial aggregation of phenytoin hypersensitivity and concordance of carbamazepine hypersensitivity in MZ twins. However, a single mutation within the coding region of the microsomal epoxide hydrolase gene is unlikely to be the sole determinant of this genetic predisposition.

Finally, the teratogenic effects of anticonvulsant drugs are well known and the potential for pharmacogenetics to stratify offspring risk on the basis of genetic susceptibility is long recognised. More recently, the identification of inbred strains of mice which are more or less sensitive to the teratogenic effects of sodium valproate has lent support to the notion that offspring liability to valproate induced teratogenicity has a genetic basis and offers the potential to identify high risk couples. The magnitude of risk conferred by genetic factors, however, remains to be determined. If such genes confer low relative risk for a person (despite a high population attributable risk) then intervention based on the identification of risk conferring alleles may not be warranted.

Conclusion

A hereditary component to epilepsy has been suspected since the time of Hippocrates, but only in the past few years has the genetic basis for this liability begun to unravel. Spectacular advances have suggested mechanisms of epileptogenesis hitherto unconsidered. Experimental data demonstrate how differences in drug response can result from inherited differences in drug sensitivity and there are emerging data on the genetic basis of harmful adverse drug reactions and teratogenesis. These developments predict a future in which epilepsy is ultimately classified on the basis of its oligogenic architecture and pharmacogenetics tailors the appropriate drug to the appropriate patient, with attendant benefits in both clinical practice and cost.

This work has been supported by an educational grant from Jansen-Cilag. We are grateful to Drs MC Walker and NW Wood for the critical reading of this manuscript.
The clinical impact of epilepsy genetics

M R JOHNSON, M R JOHNSON, J W A S SANDER and J W A S SANDER

J Neurol Neurosurg Psychiatry 2001 70: 428-430
doi: 10.1136/jnnp.70.4.428

Updated information and services can be found at:
http://jnnp.bmj.com/content/70/4/428

These include:

Supplementary Material
Supplementary material can be found at:
http://jnnp.bmj.com/content/suppl/2001/08/08/70.4.428.DC1

References
This article cites 33 articles, 7 of which you can access for free at:
http://jnnp.bmj.com/content/70/4/428#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/